| Criteria for cure of acromegaly: a consensus statement A Giustina, A Barkan, FF Casanueva, F Cavagnini, L Frohman, K Ho, ... The Journal of Clinical Endocrinology & Metabolism 85 (2), 526-529, 2000 | 1308 | 2000 |
| Treatment of acromegaly with the growth hormone–receptor antagonist pegvisomant PJ Trainer, WM Drake, L Katznelson, PU Freda, V Herman-Bonert, ... New England Journal of Medicine 342 (16), 1171-1177, 2000 | 1039 | 2000 |
| Guidelines for acromegaly management: an update S Melmed, A Colao, A Barkan, M Molitch, AB Grossman, D Kleinberg, ... Journal of Clinical Endocrinology and metabolism 94 (5), 1509-1517, 2009 | 1011 | 2009 |
| Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist AJ Van Der Lely, RK Hutson, PJ Trainer, GM Besser, AL Barkan, ... The Lancet 358 (9295), 1754-1759, 2001 | 801 | 2001 |
| Octreotide treatment of acromegaly: a randomized, multicenter study S Ezzat, PJ Snyder, WF Young, LD Boyajy, C Newman, A Klibanski, ... Annals of Internal Medicine 117 (9), 711-718, 1992 | 386 | 1992 |
| A consensus on the diagnosis and treatment of acromegaly comorbidities: an update A Giustina, A Barkan, A Beckers, N Biermasz, BMK Biller, C Boguszewski, ... The Journal of Clinical Endocrinology & Metabolism 105 (4), e937-e946, 2020 | 344 | 2020 |
| Decreased hypothalamic gonadotropin-releasing hormone secretion in male marathon runners SE MacConnie, A Barkan, RM Lampman, MA Schork, IZ Beitins New England Journal of Medicine 315 (7), 411-417, 1986 | 344 | 1986 |
| Octreotide as primary therapy for acromegaly CB Newman, S Melmed, A George, D Torigian, M Duhaney, P Snyder, ... The Journal of Clinical Endocrinology & Metabolism 83 (9), 3034-3040, 1998 | 323 | 1998 |
| Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up EV Dimaraki, CA Jaffe, R DeMott-Friberg, WF Chandler, AL Barkan The Journal of Clinical Endocrinology & Metabolism 87 (8), 3537-3542, 2002 | 300 | 2002 |
| Regulatory mechanisms of growth hormone secretion are sexually dimorphic. CA Jaffe, B Ocampo-Lim, W Guo, K Krueger, I Sugahara, ... The Journal of clinical investigation 102 (1), 153-164, 1998 | 292 | 1998 |
| Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels AL Barkan, EV Dimaraki, SK Jessup, KV Symons, M Ermolenko, CA Jaffe The Journal of Clinical Endocrinology & Metabolism 88 (5), 2180-2184, 2003 | 290 | 2003 |
| Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion AL BARKAN, IZ BEITINS, RP KELCH The Journal of Clinical Endocrinology & Metabolism 67 (1), 69-73, 1988 | 285 | 1988 |
| Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement FF Casanueva, AL Barkan, M Buchfelder, A Klibanski, ER Laws, ... Pituitary 20, 489-498, 2017 | 278 | 2017 |
| Treatment of acromegaly with dopamine agonists CA Jaffe, AL Barkan Endocrinology and metabolism clinics of North America 21 (3), 713-735, 1992 | 277 | 1992 |
| Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test E Erturk, CA Jaffe, AL Barkan The Journal of Clinical Endocrinology & Metabolism 83 (7), 2350-2354, 1998 | 275 | 1998 |
| A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly S Melmed, R Sternberg, D Cook, A Klibanski, P Chanson, V Bonert, ... The Journal of Clinical Endocrinology & Metabolism 90 (7), 4405-4410, 2005 | 263 | 2005 |
| Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate AL BARKAN, RV LLOYD, WF CHANDLER, MK HATFIELD, SS GEBARSKI, ... The Journal of Clinical Endocrinology & Metabolism 67 (5), 1040-1048, 1988 | 242 | 1988 |
| Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant AL Barkan, P Burman, DR Clemmons, WM Drake, RF Gagel, PE Harris, ... The Journal of Clinical Endocrinology & Metabolism 90 (10), 5684-5691, 2005 | 241 | 2005 |
| Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly AL Barkan, I Halasz, KJ Dornfeld, CA Jaffe, RDM Friberg, WF Chandler, ... The Journal of Clinical Endocrinology & Metabolism 82 (10), 3187-3191, 1997 | 233 | 1997 |
| Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial S Petersenn, J Schopohl, A Barkan, P Mohideen, A Colao, R Abs, ... The Journal of Clinical Endocrinology & Metabolism 95 (6), 2781-2789, 2010 | 222 | 2010 |
